FGFR1 (Ab-766) Antibody

What is the FGFR1 (Ab-766) Antibody and what epitope does it recognize?

The FGFR1 (Ab-766) Antibody is a rabbit polyclonal antibody that specifically recognizes the region surrounding the Tyrosine 766 phosphorylation site in human FGFR1 protein. The antibody was developed using a synthesized non-phosphopeptide derived from human FGFR1 with the sequence Q-E-Y(p)-L-D, corresponding to the region around the tyrosine 766 phosphorylation site. This antibody detects endogenous levels of total FGFR1 protein in human samples, making it valuable for studying FGFR1 expression and localization. The specificity for this particular epitope allows researchers to investigate FGFR1 signaling processes where Tyr766 phosphorylation plays a critical role .

What are the validated applications for the FGFR1 (Ab-766) Antibody?

The FGFR1 (Ab-766) Antibody has been validated for the following applications:

Researchers should note that the antibody has been specifically optimized and validated for Western Blotting and Immunohistochemistry applications with human samples. These techniques allow for protein detection in cell lysates and tissue sections, respectively, enabling studies of FGFR1 expression patterns and levels in various experimental contexts .

How should I optimize Western Blotting protocols when using the FGFR1 (Ab-766) Antibody?

When optimizing Western Blotting protocols with the FGFR1 (Ab-766) Antibody, several factors should be considered for reliable and reproducible results:

First, ensure proper sample preparation by using an appropriate lysis buffer containing phosphatase inhibitors if you're interested in preserving phosphorylation states. For FGFR1 detection, proteins should be denatured in sample buffer containing SDS and a reducing agent. Second, optimize protein loading (30-50μg of total protein is typically sufficient) and separation using 7.5-10% SDS-PAGE gels, as FGFR1 has a molecular weight of approximately 120-145 kDa.

For transfer, a semi-dry or wet transfer system with PVDF membrane is recommended due to the relatively large size of the FGFR1 protein. Blocking should be performed with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. For primary antibody incubation, start with a 1:1000 dilution in blocking buffer and incubate overnight at 4°C. Following appropriate washing steps, use compatible secondary antibodies such as Goat Anti-Rabbit IgG conjugated with HRP.

Finally, perform detection using enhanced chemiluminescence and optimize exposure times based on signal intensity. If background is high, consider increasing washing stringency or decreasing antibody concentration. For phospho-specific detection, BSA is preferred over milk for blocking and antibody dilution .

What controls should be included when using FGFR1 (Ab-766) Antibody in experimental designs?

A robust experimental design using the FGFR1 (Ab-766) Antibody should incorporate multiple controls:

• Positive Control: Include cell lines known to express FGFR1, such as the JMSU1 bladder cancer cell line mentioned in the literature. This confirms antibody functionality and provides a reference for expected band size.

• Negative Control: Use cell lines with low or no FGFR1 expression, or FGFR1 knockout cells where available, to confirm antibody specificity.

• Loading Control: Always include detection of housekeeping proteins (e.g., β-actin, GAPDH) to normalize for protein loading variations.

• Peptide Competition Control: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity.

• Phosphorylation-State Controls: When studying Tyr766 phosphorylation, include samples treated with FGF ligands to increase phosphorylation and samples treated with phosphatase or FGFR inhibitors to decrease phosphorylation.

• Secondary Antibody Control: Incubate some samples with secondary antibody only to identify non-specific binding.

• Transfection Controls: Consider using cells transfected with wild-type FGFR1 and the Y766F mutant (where tyrosine is replaced with phenylalanine) to definitively establish the specificity of phospho-specific antibodies targeting this site .

What are common sources of false positives/negatives when using the FGFR1 (Ab-766) Antibody, and how can they be addressed?

Several factors can contribute to false results when using the FGFR1 (Ab-766) Antibody:

Sources of False Positives:

• Cross-reactivity with other FGFR family members due to sequence homology

• Excessive antibody concentration leading to non-specific binding

• Insufficient blocking or washing

• Sample overloading causing background issues

• Degraded secondary antibodies causing non-specific signals

Sources of False Negatives:

• Improper sample preparation or protein degradation

• Insufficient protein loading

• Inefficient protein transfer to membrane

• Loss of epitope accessibility due to fixation (for IHC)

• Antibody degradation due to improper storage

Mitigation Strategies:

• Always validate antibody specificity using positive and negative controls

• Optimize antibody concentration through titration experiments

• Ensure proper sample handling to prevent protein degradation (use protease inhibitors)

• For phospho-specific detection, use fresh samples and maintain phosphorylation status with phosphatase inhibitors

• Store the antibody at -20°C as recommended and avoid repeated freeze-thaw cycles

• For IHC applications, optimize antigen retrieval methods to ensure epitope accessibility

• Consider using alternative detection methods to confirm results obtained with this antibody

How should researchers interpret FGFR1 (Ab-766) Antibody results in the context of FGFR1 signaling pathways?

Interpreting results from FGFR1 (Ab-766) Antibody experiments requires understanding the biological context of FGFR1 signaling:

The antibody detects FGFR1 protein around the Tyr766 site, which is a critical phosphorylation site involved in PLC binding and activation. Tyr766 also plays a role in the negative regulation of FGFR1 activity in vivo. Therefore, detection of FGFR1 using this antibody provides information about the total FGFR1 protein levels, but not necessarily its activation state.

When interpreting experimental results:

• Expression levels: Changes in band intensity in Western blots may indicate alterations in FGFR1 expression, which could suggest modified receptor availability for signaling.

• Molecular weight shifts: FGFR1 typically appears at 120-145 kDa, with variations potentially indicating post-translational modifications such as glycosylation or ubiquitination.

• Pathway context: Consider analyzing multiple components of the FGFR1 signaling pathway, including downstream effectors like PLCγ, MAPK, and PI3K/AKT to provide a comprehensive picture of pathway activation.

• Functional correlations: Correlation between FGFR1 detection and cellular phenotypes (proliferation, survival, migration) provides functional context for interpreting antibody results.

• Comparison with phospho-specific antibodies: To fully assess FGFR1 activation status, researchers should consider using phospho-specific antibodies targeting Tyr766 alongside this total FGFR1 antibody .

How can the FGFR1 (Ab-766) Antibody be used to study the functional significance of Tyr766 phosphorylation in FGFR1 signaling?

The FGFR1 (Ab-766) Antibody provides a valuable tool for investigating the functional significance of Tyr766 phosphorylation through several advanced approaches:

• Comparative analysis with phospho-specific antibodies: Using both the FGFR1 (Ab-766) Antibody (detecting total FGFR1) and phospho-specific antibodies against Tyr766 allows researchers to calculate the ratio of phosphorylated to total FGFR1, providing a measure of receptor activation.

• Site-directed mutagenesis studies: The antibody can be used to confirm expression of FGFR1 Y766F mutants in comparative studies with wild-type FGFR1. This approach, as described in the literature, allows researchers to specifically assess the role of Tyr766 phosphorylation by comparing cellular responses between cells expressing wild-type versus Y766F mutant receptors.

• Temporal signaling dynamics: By using the antibody in time-course experiments following FGF stimulation, researchers can monitor changes in FGFR1 levels relative to phosphorylation events, helping to establish the sequence of signaling events.

• Interaction studies: The antibody can be used in immunoprecipitation followed by Western blotting to identify FGFR1 interaction partners, particularly those that might be dependent on Tyr766 phosphorylation, such as PLCγ.

• Subcellular localization: Through immunofluorescence or subcellular fractionation followed by Western blotting, researchers can investigate how Tyr766 phosphorylation affects FGFR1 trafficking and localization .

What approaches can be used to integrate FGFR1 (Ab-766) Antibody data with other molecular techniques for comprehensive pathway analysis?

To achieve comprehensive analysis of FGFR1 signaling pathways, researchers should consider integrating FGFR1 (Ab-766) Antibody data with complementary techniques:

• Multi-omics integration: Combine antibody-based protein detection with:

  • Transcriptomics (RNA-seq) to correlate FGFR1 protein levels with mRNA expression

  • Phosphoproteomics to map broader pathway activation patterns

  • Interactomics (mass spectrometry after immunoprecipitation) to identify novel binding partners

• Functional genomics approaches:

  • CRISPR/Cas9-mediated gene editing to create FGFR1 knockout models or specific Tyr766 mutants

  • RNA interference to temporarily reduce FGFR1 expression and correlate with antibody detection

  • Overexpression systems with tagged FGFR1 variants to study protein dynamics

• Advanced imaging techniques:

  • Proximity ligation assays (PLA) to visualize FGFR1 interactions with downstream effectors

  • FRET/BRET to study real-time protein-protein interactions involving FGFR1

  • Super-resolution microscopy to analyze FGFR1 clustering and membrane organization

• Computational modeling:

  • Use antibody-derived quantitative data on FGFR1 expression and phosphorylation as inputs for mathematical models

  • Predict pathway dynamics and simulate the effects of perturbations

  • Identify potential feedback mechanisms and pathway crosstalk

• Translational research integration:

  • Correlate FGFR1 detection in patient samples with clinical outcomes

  • Develop biomarker strategies based on FGFR1 expression or phosphorylation patterns

  • Evaluate therapeutic responses to FGFR inhibitors relative to FGFR1 status

How can the FGFR1 (Ab-766) Antibody be used to investigate FGFR1's role in cancer progression and therapeutic resistance?

The FGFR1 (Ab-766) Antibody offers valuable applications for cancer research through several methodological approaches:

• Tissue Microarray Analysis: By applying the antibody to cancer tissue microarrays, researchers can evaluate FGFR1 expression across multiple tumor samples simultaneously, correlating expression patterns with clinical parameters such as stage, grade, and patient outcomes.

• Therapy Response Studies: The antibody can be used to monitor changes in FGFR1 expression before and after treatment with FGFR inhibitors or other targeted therapies, potentially identifying markers of resistance development.

• Cancer Cell Line Panels: Screening diverse cancer cell line panels with the antibody can identify cancer types with FGFR1 overexpression or abnormal localization patterns, suggesting potential responsiveness to FGFR-targeted therapies.

• Paired Primary-Metastatic Sample Analysis: Comparing FGFR1 expression between primary tumors and their metastases can provide insights into the role of FGFR1 in metastatic progression.

• Combination with Genetic Analysis: Correlating FGFR1 protein expression (detected by the antibody) with FGFR1 amplification status (determined by FISH or genomic analysis) can identify relationships between genetic alterations and protein expression.

Research has specifically implicated FGFR1 in urothelial cancer progression, with studies showing that FGFR1 promotes proliferation and survival in this cancer type, suggesting it may represent a useful therapeutic target in some cases of urothelial carcinoma .

What methodologies can be employed to study the interaction between FGFR1 and PLCγ using the FGFR1 (Ab-766) Antibody?

The interaction between FGFR1 and PLCγ, which is mediated through Tyr766 phosphorylation, can be studied using the FGFR1 (Ab-766) Antibody through several methodological approaches:

• Co-immunoprecipitation (Co-IP) Studies:

  • Immunoprecipitate FGFR1 using the Ab-766 antibody, then probe for PLCγ in the precipitate

  • Alternatively, immunoprecipitate PLCγ and detect FGFR1 in the precipitate

  • Compare results between FGF-stimulated and unstimulated conditions to assess interaction dynamics

• Proximity Ligation Assay (PLA):

  • Use the FGFR1 (Ab-766) Antibody together with an anti-PLCγ antibody to visualize and quantify direct protein interactions in situ

  • This technique allows detection of interactions with subcellular resolution

• Mutational Analysis with Functional Readouts:

  • Compare PLCγ binding between wild-type FGFR1 and the Y766F mutant

  • Measure downstream signaling consequences such as calcium release or DAG production

  • Correlate binding efficiency with functional outcomes

• Kinetic Analysis of Interaction:

  • Perform time-course experiments following FGF stimulation

  • Use the antibody in combination with phospho-specific antibodies to correlate Tyr766 phosphorylation timing with PLCγ recruitment

  • Analyze the temporal relationship between receptor activation, Tyr766 phosphorylation, and PLCγ binding

• Inhibitor Studies:

  • Use specific FGFR1 kinase inhibitors to block phosphorylation

  • Assess how inhibition affects PLCγ binding and activation

  • Compare with effects of PLC inhibitors on downstream signaling

These approaches collectively can provide comprehensive insights into how the Tyr766 residue mediates the interaction between FGFR1 and PLCγ, and the functional consequences of this interaction for downstream signaling events .

How does the FGFR1 (Ab-766) Antibody compare with other commercially available FGFR1 antibodies in terms of specificity and applications?

When selecting an appropriate FGFR1 antibody for research, understanding the comparative advantages of the FGFR1 (Ab-766) Antibody is essential:

The FGFR1 (Ab-766) Antibody offers specific advantages for detecting total FGFR1 protein in the context of Tyr766 phosphorylation studies. Unlike phospho-specific antibodies that only detect the activated form, this antibody allows quantification of total FGFR1 levels regardless of phosphorylation state. In contrast, the Phospho-FGFR1 (Tyr766) (1E5) antibody specifically detects only the phosphorylated form but requires transfection-level expression.

For researchers interested in studying different domains of FGFR1, antibodies targeting specific regions like the extracellular domain (AA 22-376) or the N-terminal region (AA 19-48) provide complementary tools. When selecting between these options, consider whether your research question focuses on total protein levels, specific phosphorylation events, or particular domains of the receptor .

What validation steps should researchers perform to ensure reliable results with the FGFR1 (Ab-766) Antibody in their specific experimental system?

Before incorporating the FGFR1 (Ab-766) Antibody into a research program, comprehensive validation in the specific experimental system is essential:

• Antibody Titration:

  • Perform dilution series experiments (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Identify optimal concentration that maximizes specific signal while minimizing background

  • Document optimal conditions for future reference

• Specificity Validation:

  • Compare detection between FGFR1-expressing and non-expressing/knockdown samples

  • Conduct peptide competition assays using the immunizing peptide

  • If possible, test detection in FGFR1 knockout models as negative controls

• Cross-Reactivity Assessment:

  • Test samples expressing other FGFR family members (FGFR2, FGFR3, FGFR4)

  • Evaluate potential cross-reactivity with structurally similar proteins

• Reproducibility Testing:

  • Perform technical replicates to assess consistency

  • Conduct experiments on different days to evaluate day-to-day variability

  • Test different sample preparation methods to determine optimal protocols

• Application-Specific Validation:

  • For Western blotting: Confirm expected molecular weight (120-145 kDa for FGFR1)

  • For IHC: Compare with literature-reported localization patterns

  • Validate results with orthogonal methods (e.g., mRNA analysis, mass spectrometry)

• Functional Correlation:

  • Correlate antibody detection with functional readouts (e.g., downstream signaling)

  • Compare results after stimulation with FGF ligands or FGFR inhibitor treatment

• Lot-to-Lot Variation Assessment:

  • When receiving new antibody lots, perform side-by-side comparison with previously validated lot

  • Document any differences in sensitivity or specificity

By systematically performing these validation steps, researchers can ensure reliable and reproducible results when using the FGFR1 (Ab-766) Antibody in their specific experimental systems .

How might the FGFR1 (Ab-766) Antibody be utilized in emerging research areas such as single-cell analysis and spatial proteomics?

The FGFR1 (Ab-766) Antibody has potential applications in cutting-edge research areas:

In single-cell analysis, the antibody could be adapted for single-cell Western blotting or used in mass cytometry (CyTOF) with metal-conjugated formats to quantify FGFR1 expression in heterogeneous cell populations. This would allow researchers to correlate FGFR1 expression with other markers at the single-cell level, revealing subpopulations with distinct signaling profiles.

For spatial proteomics applications, the antibody could be employed in multiplexed immunofluorescence or imaging mass cytometry to visualize FGFR1 distribution within tissues while preserving spatial context. This approach would reveal cell-type specific expression patterns and potential interactions with the microenvironment, particularly important in tumor tissues where FGFR1 signaling may vary between tumor cells and stroma.

The antibody could also be incorporated into emerging microfluidic platforms for spatially-resolved proteomics, helping to map FGFR1 expression and Tyr766-mediated signaling within complex tissue architectures. Additionally, coupling with in situ proximity ligation assays would allow visualization of specific FGFR1 interactions at subcellular resolution.

As multiomics approaches continue to evolve, the antibody could contribute to integrated analyses correlating protein-level data with transcriptomics, metabolomics, and genomics at increasingly fine spatial resolution, providing comprehensive insight into FGFR1 biology in normal and disease states .

What methodological adaptations might be required to utilize the FGFR1 (Ab-766) Antibody in high-throughput screening or precision medicine applications?

Adapting the FGFR1 (Ab-766) Antibody for high-throughput and precision medicine applications would require several methodological refinements:

For high-throughput screening applications, the antibody could be reformatted for automated Western blotting platforms or adapted to ELISA-based detection systems. This would require optimization of antibody concentration, incubation times, and detection systems for consistent results across large sample sets. Miniaturization onto microwell or microarray formats would allow simultaneous analysis of FGFR1 expression across hundreds or thousands of samples, facilitating drug screening efforts targeting FGFR1 or its signaling pathway.

In precision medicine contexts, the antibody protocol would need validation across diverse patient-derived samples and standardization for clinical laboratory implementation. This would involve:

• Protocol standardization: Developing robust, reproducible staining protocols with defined positive and negative controls for diagnostic reliability

• Quantitative scoring systems: Establishing numerical scoring methods to objectively assess FGFR1 expression levels in patient samples

• Correlation with genomic data: Integrating antibody-based protein detection with genomic information on FGFR1 amplification or mutation status

• Companion diagnostic development: Potentially adapting the antibody for use as a companion diagnostic to identify patients likely to respond to FGFR-targeted therapies

• Automation compatibility: Ensuring the staining protocol is compatible with automated immunohistochemistry platforms used in clinical laboratories

Each of these adaptations would require extensive validation to ensure the antibody maintains its specificity and sensitivity characteristics when transitioned to high-throughput or clinical applications. Additionally, standardization across different laboratories would be necessary to ensure consistent results and interpretations in the precision medicine context .